Roche receives FDA clearance for additional Alzheimer's disease cerebrospinal fluid assays, supporting timely diagnosis and treatment decision-making


27 June 2023 - The Elecsys tTau/Abeta42 ratio helps clinicians define Alzheimer's disease biologically and expands Roche's Alzheimer's CSF portfolio to include biomarkers for all three main pathological processes of Alzheimer's: amyloid plaques, tau tangles and neurodegeneration.

Roche today announced that its Elecsys beta-Amyloid (1-42) CSF II and Elecsys Total-Tau CSF assays have received US FDA 510(k) clearance.

Read Roche press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Diagnostic agent